Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON PLC (ICLR) delivers essential clinical research services across 100+ countries, supporting pharmaceutical and biotechnology development through all trial phases. This news hub provides investors and industry professionals with timely updates on operational milestones, financial performance, and strategic initiatives shaping global drug development.
Access authoritative reporting on regulatory submissions, partnership announcements, and clinical trial advancements directly impacting ICON's market position. Our curated feed eliminates information fragmentation by centralizing earnings calls, governance updates, and technology implementations critical for evaluating contract research organizations.
Key coverage areas include phase III trial initiations, FDA/EMA regulatory interactions, acquisition strategies, and capacity expansion projects. Bookmark this page for real-time updates on ICON's patient recruitment innovations and quality control enhancements that maintain compliance with evolving global standards.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, has been recognized as a top-performing CRO for phase 1 clinical trials according to an independent Industry Standard Research (ISR) report. The company achieved the highest overall sponsor satisfaction score of 7.4/10 among large CROs.
The comprehensive analysis, based on feedback from 159 industry professionals, revealed ICON's superior performance across 17 operational metrics, leading in 14 categories. The company demonstrated excellence in delivery metrics, staff characteristics, and accessibility metrics. Notably, ICON was the only large CRO to improve across all four brand strength metrics compared to 2024, marking its sixth consecutive year of outperforming weighted average scores in phase 1 trials.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, has received multiple prestigious awards in the first half of 2025. The company earned the AI Project of the Year Award for its enterprise-grade AI Assistant implementation, and was recognized on TIME Magazine's sustainability rankings, placing 57th out of 500 companies globally.
Notable achievements include being named Best CRO in APAC at the 2025 Asia Pacific Biopharma Excellence Awards and recognition as a Top-Rated Company for Women in the 2025 Ambition Box Employee Choice Awards. Additionally, over 30 ICON employees received awards at the PharmaTimes International Clinical Researcher of the Year competition.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, has announced that its CEO, Dr. Steve Cutler, will present at the William Blair 45th Annual Growth Stock Conference. The presentation is scheduled for Wednesday, June 4, 2025, at 10:40 AM CT. The company will provide updates and links to the live webcast, where available, on the Investor section of their website under the "Events" tab.
ICON (NASDAQ: ICLR) has released its ICON Cares 2024 Report, highlighting significant achievements in environmental, social, and governance (ESG) goals. The company received a 72/100 score from EcoVadis (silver medal) and a B- score on CDP Climate Change response. In 2024, ICON supported over 1,270 clinical studies involving more than 416,000 patients, contributing to 19 medicine approvals.
Notable environmental achievements include exceeding their near-term SBTi target with a 70.06% reduction in Scope 1 & 2 GHG emissions, achieving 84.67% renewable electricity consumption, and reducing laboratory kit wastage by 15-20%. The company expanded its AI and robotic process automation capabilities while strengthening governance protocols.
ICON plc (NASDAQ: ICLR) has released findings from a survey of 155 biotech and pharma professionals regarding multi-indication cardiometabolic R&D for obesity therapies. The survey reveals that 83% of sponsors are pursuing multi-indication approaches in obesity research, but many underestimate the complexity of these strategies.
Key findings show that 90% of respondents are not implementing non-traditional study arms like master protocols, while only 14% pursue multiple indications based on longitudinal data. Furthermore, only 19% follow patients for more than three years. Despite these challenges, 77% of respondents believe multi-indication R&D would lower healthcare costs.
In response, ICON has launched their new Centre for Obesity, featuring an infrastructure of 100 sites and a developing database of 10,000 pre-screened patients across obesity-related comorbidities to facilitate rapid multi-indication research.
ICON reported mixed Q1 2025 financial results with net business wins of $2,022 million and a book-to-bill ratio of 1.01. Revenue decreased 4.3% year-over-year to $2,001.3 million, while adjusted EBITDA was $390.7 million (19.5% of revenue).
Key highlights include:
- Closing backlog of $24.7 billion, up 6.0% from Q1 2024
- GAAP net income of $154.2 million ($1.90 per diluted share)
- Adjusted net income of $258.3 million ($3.19 per diluted share)
- Net debt of $2.9 billion with a net debt to adjusted EBITDA ratio of 1.7x
The company updated its 2025 guidance, now expecting revenue between $7,750-$8,150 million (representing -6.4% to -1.6% YoY) and adjusted EPS of $12.75-$14.25. Performance was impacted by market volatility, customer decision delays, and elevated cancellations. The company repurchased $250 million worth of stock at an average price of $184.
ICON plc (NASDAQ: ICLR) has scheduled its first quarter 2025 earnings release and conference call. The company will release its Q1 2025 financial results after market close on Wednesday, April 30, 2025. A conference call and webcast to discuss the results will be held the following day on Thursday, May 1, 2025 at 8:00am ET. A webcast replay will be available approximately one hour after the call concludes. Any updates or changes to these events will be posted on the Investor section of ICON's website under 'Events'.
BetterInvesting Magazine has selected Lowe's Cos. (NYSE: LOW) as its 'Stock to Study' for the June/July 2025 double issue, suggesting the stock warrants further investigation from a valuation perspective. The magazine provides comprehensive fundamental data including sales, earnings, pre-tax profit, and return on equity through the National Association of Investors platform.
Additionally, the publication's Editorial Advisory and Securities Review Committee has identified ICON PLC (NASDAQ: ICLR) for fundamental review in the same issue, specifically from an undervalued perspective. The committee's analysis is conducted by six CFA-qualified members.
ICON (NASDAQ: ICLR) has become the first large Clinical Research Organization to fully integrate Medidata Clinical Data Studio into its clinical workflows. This strategic implementation allows ICON to leverage AI-powered technology for unified data management across Medidata and non-Medidata sources.
The integration enhances ICON's ability to streamline data review, central monitoring, and medical review processes through AI and statistical modeling. This advancement is particularly significant for ICON's Clinical Data Science group, which specializes in risk-based quality management.
The partnership builds on a 20-year relationship between ICON and Medidata, during which they have collaborated on more than 1,700 studies, with over 400 currently active studies across various therapeutic areas including oncology, central nervous system, and vaccine therapies. ICON also utilizes Medidata eCOA and Medidata Designer for clinical operations management.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
